ABSTRACT. To determine whether epidermal growth factor (EGF) or EGF-like transforming growth factors (TGFs) are present in ovine fetal tissues, we have tested acid-ethanol extracts of ovine fetal kidney for the ability to induce anchorage-independent growth of normal rat kidney fibroblasts in soft agar and to compete with "' 1-mouse EGF for binding to receptors in sheep liver. The fetal kidney extract (20-1000 pg protein/ml) stimulated a dose-dependent increase in the number of soft agar colonies of normal rat kidney cells. Approximately 70% of these colonies measured r 3100 pM2. The fetal kidney extract was dissolved in 1 M acetic acid and chromatographed on Bio-Gel P 10. Two peaks of TGF-like activity, with approximate MW 14.5K (peak 1) and 9K (peak 2), eluted from the column. Half-maximal effects of pooled peaks 1 and 2 on colony formation were achieved using 100 and 20 pg protein/ml, respectively. Peaks I and 2 also competed with 'ZSI-mouse EGF for binding to EGF receptors in ovine fetal liver but had no activity in a homologous mouse EGF radioimmunoassay sensitive to 15 pg mouse EGF. Neither TGF activity nor EGF receptor binding activity was detected in Bio-Gel fractions co-eluting with '2sI-mouse EGF. Specific "'1-EGF binding sites in fetal liver were detected as early as midgestation, and the number of EGF binding sites increased markedly in late gestation, exceeding the number of EGF binding sites in the livers of pregnant ewes. These findings demonstrate the presence of TGF-like activity in ovine fetal kidney and high affinity EGF receptors in ovine fetal liver. The absence of EGF receptor activity in Bio-Gel fractions coeluting with 12sI-mouse EGF suggests that TGF may predominate in the ovine fetus and may play an EGF-like role in ovine fetal development. (Pediatr Res 22: 609-615, 1987) animals implicate a role for EGF in the control of cellular and tissue growth, the regulation of gastric acid secretion. and the modulation of the synthesis and secretion of a number of hormones and peptide growth factors (I). The role of EGF in the fetus, however, is poorly understood. EGF binds to specific receptors in fetal mouse (2, 3) and rat (4) tissues and stimulates glycogen synthesis (4) and somatomedin production in fetal rat hepatocytes (5) and human fetal fibroblasts (6) . In addition, EGF has mitogenic effects in fetal rat chondrocytes (7) and human fetal adrenal cells (8) and stimulates phospholipid synthesis in fetal rat lung explants (9) . However, the concentration of immunoreactive EGF in newborn mouse urine (lo), kidney (10) . and submaxillary gland (I I) and in human cord blood (12) and human newborn urine (I 3) is low and increases markedly during postnatal life (10-1 3). These findings suggest that EGF may exert its major role on growth and development after birth. Recent studies have demonstrated that extracts of normal mouse (14) (15) (16) and rat embryos (17) contain EGF-like TGFs which bind to EGF receptors and share many biologic actions with EGF itself (1 8-24 ). These observations suggest a possible role for TGF or a related growth factor as a "fetal EGF."
The demonstration that EGF promotes the growth and maturation of the liver, lung, and epidermal tissues of the fetal lamb in vivo (25, 26) suggests a role for EGF or the EGF-like TGFs in ovine fetal development. However, the presence of endogenous EGF or TGF in the ovine fetus has not been established. To determine if EGF or EGF-like TGFs are present in ovine fetal tissues, we have tested acid-ethanol extracts of ovine fetal kidney for the ability to induce anchorage-independent growth of normal rat kidney fibroblasts in soft agar and to compete with radiolabeled EGF for binding to receptors in fetal and postnatal sheep liver.
10 FREEMARK AND COMER
Detection o f TGF-like activity. Aliquots of ovine fetal kidney (days 123-1 37 of gestation, n = 3) were extracted by a modification of the method of Roberts ef al. (28) . Fetal kidneys were homogenized at 0" C in a solution (4 ml/g wet weight) containing 375 ml of 95% ethanol, 7.5 ml concentrated HCI, 33 mg of phenylmethylsulfonyl fluoride, and 20 pg/ml soybean trypsin inhibitor. The volume was adjusted to 6 ml/g with cold distilled water and the tissue was extracted overnight at 4" C. The suspension was centrifuged at 10,000 x g for 20 min at 4" C. The pellet was re-extracted for 2 h with a solution containing 375 ml of 95% ethanol, 105 ml distilled water, and 7.5 ml concentrated HCI (2 ml/g original weight). Supernatants from both extractions were pooled and adjusted to pH 5.2 with concentrated NH40H, and 1 ml of 2 M ammonium acetate, pH 5.2 was added per 100 ml of supernatant. The suspension was centrifuged at 10,000 x g for 20 min at 4" C. The supernatant was precipitated at -20" C for 24 h with 4 volumes of cold ethanol and 2 volumes of cold anhydrous ether. The precipitate was collected by centrifugation at 10,000 x g for 20 min at 4" C, redissolved in 1 M acetic acid, dialyzed against 0.2 M acetic acid using Spectropor no. 6 dialysis tubing (MW cutoff 1000, Spectrum Medical, Los Angeles, CA), and lyophilized. The yield of protein was 3.3-4.2 mg/g wet weight.
The acid-ethanol extract was dissolved in 1 M acetic acid and applied to a Bio-Gel P10 column (2 x 46 cm) previously equilibrated in I M acetic acid. Fractions (2.4 ml) eluting from the column were lyophilized and assayed for colony-forming activity. Active fractions were pooled and the effects of these pooled fractions were compared to the effect of the crude acid-ethanol extract itself.
Assays of colony-forming activity in soft agar were performed in Dulbecco's modified Eagle's medium containing 10% calf serum (supplemented medium) as described by Todaro et al. (18) . One ml of supplemented medium containing 0.3% (w/v) agar (Difco, BioRad Richmond, CA), 8 x lo3 normal rat kidney fibroblasts, and varying amounts of fetal kidney extract or pooled Bio-Gel fractions were pipetted onto a base layer of medium containing 0.5% agar in 22.6-mm diameter plastic culture dishes (Costar Data Packaging Corp., Cambridge, MA). The cells were incubated at 37" C in a humidified 5% C02/95% air atmosphere, and plates were overlaid with supplemented medium on day 7. The assay was read unfixed and unstained on day 10. The total number of colonies (more than six cells) ( 16) in eight microscopic fields, as well as the number of colonies measuring more than 63 pM in diameter (>3 100 pM2) and 94 pM in diameter (>7000 pM2), were counted.
Receptor assays. '251-EGF was prepared using 1,3,4,6-tetrachloro3,6,-diphenyl-glycouril (Iodo-Gen, Pierce Chemical Co., Rockford, IL) as the catalyst. Forty pl of a solution containing 3.5 pg of EGF and 45 p1 of 0.3 M phosphate buffer were added to a 12 x 75 tube coated with I pg Iodo-Gen. The iodination reaction was initiated by the addition of 4 p1 (400 pCi) of '2510dine (Amersham Corp., Arlington Heights, IL). The mixture was gently shaken every 30 s for 4 min and the reaction was terminated by the addition of 1.0 ml of cold phosphate buffer. 1251-EGF was purified by gel filtration on a Sephadex G-25 fine column (30 x 1.5 cm) eluted with 0.01 M phosphate pH 7.6 in normal saline containing 10 mM EDTA and 0.1 % bovine serum albumin. The percentage of radioactivity incorporated into I2'I-EGF was 45-60%, and the specific activity of the iodinated hormone, calculated from the elution profiles of the radiolabeled hormone and free I2'I on Sephadex G-25, was 55-70 pCi/pg protein. This preparation of radiolabeled EGF migrated as a single band on polyacrylamide gel electrophoresis. The purity of the radiolabeled EGF was confirmed by autoradiography of the dried gels using purified mouse EGF as a standard.
Particulate microsomal fractions of ovine fetal liver were prepared by differential centrifugation as described by Tsushima and Friesen (29) . Groups of three or four pregnant Dorset ewes at 70-79, 94-98, 1 18-1 23, and 130-141 days of gestation (term = 145 days), groups of three neonatal male lambs at 1, 3, and 7-9 days of age, and four sheep at 37 days to 7 months of age were killed rapidly by the intrathecal administration of Letalis (sodium pentobarbital, Barber Veterinary Supply Co., Richmond, VA). Livers of fetal, pregnant, and postnatal nonpregnant sheep were rapidly removed and immediately frozen at -70" C. Frozen liver samples were subsequently thawed and homogenized in ice-cold 0.3 M sucrose containing 2 mM EDTA, pH 7.4. The homogenate was filtered through cheesecloth and centrifuged at 1500 x g for 30 min. The supernatant was recovered and centrifuged at 1 1,000 x g for 30 min. The resulting supernatant was then recentrifuged at 100,000 x g for 60 min and the pellet was resuspended in 25 m M Tris-HC1, pH 7.6, containing 10 mM MgCI2 and 0.1 % BSA, pH 7.6 (assay buffer). The protein contents of the membrane suspensions were determined by the method of Bradford (30) .
The percentage of homogenate protein remaining in the 100,000 x g membrane fractions and the membrane activity of 5'nucleotidase (3 1) were examined in livers of fetal lambs at 96 and 137 days of gestation and postnatal sheep at 7 months of age. The percentage of homogenate protein remaining in the hepatic microsomal fractions averaged 6.84 k 0.91% (mean + SE, n = 9) and did not differ significantly among the three groups. The S'nucleotidase activities in hepatic microsomes from fetal lambs at 96 and 137 days of gestation were 5.86 + 0.71 (mean +_ SE, n = 3), 6 .84 t-0.88 (mean -t SE, n = 3) pmol phosphorus/mg/h, respectively, while the S'nucleotidase activity in hepatic microsomes from postnatal sheep at 7 months of age was 4.99 + 1.02 (mean + SE, n = 3) pmol phosphorus/mg/h. Iz5I-EGF (50,000 cpm, approximately 2-3 ng) was incubated with membrane protein and unlabeled hormone in assay buffer (total volume 0.5 ml) for 30 min to 24 hr at 4, 23, and 37" C. Incubations were terminated by the addition of 2 ml of ice-cold assay buffer to each assay tube and the tubes were centrifuged at 3000 x g for 30 min. After the pellets were washed twice with ice-cold assay buffer, the radioactivity in each pellet was determined by y scintillation spectrometry.
The total binding of I2'I-EGF was expressed as the percent of iodinated hormone bound to hepatic membranes. Specific binding was calculated by subtracting the amount of binding which occurred in the presence of excess (500 ng) unlabeled hormone (nonspecific binding) from the total binding. Specific binding of I2'I-EGF at all stages of development increased linearly with increasing concentrations of membrane protein, reaching maximum binding with 0.5-1.25 mg of protein per assay tube. Maximal specific binding occurred at 2 h of incubation at room temperature or at 24 h of incubation at 4" C.
Dose-response curves for the binding of '251-EGF were analyzed by the method of Scatchard (32) , and Scatchard plots were utilized to determine the affinity and number of hormone binding sites.
The reversibility of I2'I-EGF binding to hepatic membranes was assessed by incubating approximately 75,000 cpm (approximately 3-4.5 ng) of I2'I-EGF with I mg membrane protein for 20 h at 4" C. At the end of the incubation period, the reaction mixture was diluted with 2 ml of assay buffer containing 500 ng of unlabeled EGF. The specific binding of 1251-EGF to hepatic membranes remaining after a subsequent 4-h incubation at room temperature was compared to the specific binding of '251-EGF at the end of the initial 20-h incubation period. The binding of '251-EGF was reversible within 2 h following the addition of a 100-fold excess of unlabeled hormone.
To determine the extent of degradation of the radiolabeled EGF during incubation with hepatic microsomes, approximately 75,000 cpm of I2'I-EGF was incubated with 500 pg hepatic membrane protein (postnatal sheep age 7 months) in the absence of unlabeled EGF for 20 h at 4" C. The reaction was terminated by the addition of cold assay buffer followed by centrifugation at 3000 X g. An aliquot of the supernatant containing I2'I-EGF was then incubated with fresh hepatic membranes in the presence specific, saturable, reversible, and time and temperature dependent. Unlabeled mouse EGF caused a dose-dependent inhibition of the binding of 1251-EGF, with half-maximal displacement of radiolabeled EGF by 1.7 ng/ml (0.3 nM) unlabeled EGF (Fig.  3) . In contrast, insulin-like growth factors I and 11, insulin, ovine growth hormone, and ovine placental lactogen were without effect.
The binding of '251-EGF to sheep liver microsomes was inhibited by lyophilized fractions eluting from the Bio-Gel column. As shown in Figure 2 , two peaks of EGF-like receptor-binding activity, with approximate MW 14.5 and 9 K, were detected.
The two peaks of receptor binding activity coeluted with the two peaks of TGF-like activity, but neither TGF-like activity nor EGF receptor binding activity coeluted with 1251-mouse EGF.
To be certain that the apparent receptor-binding activity identified in Bio-Gel fractions did not result from degradation of the EGF tracer, we compared the specific binding of EGF tracer which had been preincubated with active Bio-Gel fractions with that of EGF tracer preincubated with assay buffer alone. The specific binding of the EGF tracer previously exposed to aliquots of Bio-Gel pooled peak 1 (14.5 -1 2.3% per mg protein) was similar to that of EGF tracer preincubated with assay buffer alone ( 1 5.3 t 2.1 % per mg protein).
To be sure that the active Bio-Gel fractions did not inhibit the binding of '251-EGF by causing proteolysis of hepatic EGF receptors, we examined the binding of radiolabeled EGF to hepatic microsomes preincubated with active Bio-Gel fractions and to microsomes preincubated with receptor assay buffer alone. The specific binding of '"1-EGF to hepatic microsomes preincubated with Bio-Gel pooled peak 1 (2 1.4 +_ 1.5% per mg protein, n = 3) was similar to the specific binding of '251-EGF to hepatic microsomes preincubated with assay buffer alone (20.8 + 2.1 % per mg protein, n = 3).
When 30 mg of acid-ethanol extract protein was applied to the Bio-Gel column, a total of 9.8 ng equivalents of EGF receptor binding activity was recovered in the active column fractions. Thus the estimated concentration of EGF binding activity in the acid-ethanol extract, assuming no significant losses during chromatography, was 0.33 ng/mg protein.
To determine whether Bio-Gel fractions which displaced 1251-TGF ACTIVITY IN OVlNE FETUS 6 13 mouse EGF from hepatic receptors also competed with '251-mouse EGF for binding to specific antimouse EGF antibody, we examined the effect of receptor-active fractions in a homologous mouse EGF radioimmunoassay sensitive to 10-15 pg of mouse EGF. As shown in Figure 4 , the receptor-active Bio-Gel fractions had no detectable activity in the mouse EGF RIA. The binding of '251-EGF to livers of fetal sheep at varying stages of development was compared to the binding of E G F to livers of neonatal, postnatal nonpregnant, and pregnant sheep. As shown in Figure 5 , specific "51-EGF binding sites in fetal liver were detected as early as midgestation, and the number of EGF binding sites increased markedly in late gestation, reaching a peak of 80-100 fmol/mg protein at the time of birth. The number of E G F binding sites in fetal liver exceeded the number of EGF Acid-ethanol Extract ( ) or Bio-Gel Peaks 1 ( ) and 2 ( 1, In all cases the SE of the mean was less than 10% of the mean value.
binding sites in the livers of pregnant ewes, particularly in late gestation (Fig. 6 ). Scatchard plots of EGF binding curves (Fig. 7) at all stages of development were linear and were parallel to one another, indicating that there were no significant changes in the affinity of the E G F receptor during development.
DISCUSSION
The TGFs are a family of low molecular weight polypeptides which share the capacity to stimulate anchorage-independent growth of normal rat kidney fibroblasts in soft agar. TGF-like activity has been detected in extracts of whole mouse and rat embryos (14) (15) (16) (17) and TGFs have been purified from conditioned media of murine sarcoma virus transformed cells and certain human tumor cells and from human placenta and human plate-lets (19) . The results of the studies reported herein demonstrate the presence of TGF-like activity in the kidney of the ovine fetus. Acid-ethanol extracts of fetal kidney stimulated a dose-dependent increase in the number and size of colonies of NRK fibroblasts in soft agar. Like the TGFs identified in acid-ethanol extracts of conditioned media of transformed cells and of mouse embryos, the ovine fetal TGF is stable in 1 M acetic acid and elutes as two peaks of colony-forming activity when chromatographed on BioGel. The apparent molecular weights of the two peaks of ovine fetal TGF activity (MW 14.5 and 9 K) are comparable to the molecular weights of the TGFs detected in acid-ethanol extracts of mouse embryos (MW 20 and 10 K) (16, 34) . However, the MW of the TGF-like activity in ovine fetal kidney cannot be determined precisely by gel-exclusion chromatography on BioGel. Some proteins, such as mouse EGF, adsorb to Bio-Gel and migrate anomalously on Bio-Gel columns. Thus, the apparent 14.5 and 9 K peaks of activity may not accurately represent the actual molecular mass of the TGF-like activity. In addition, it is possible that the 14.5 and 9 K peaks of activity may represent proteolytic fragments of a larger MW species. On the other hand, the two molecular weight forms of TGF activity in tissues of the ovine and mouse fetuses may represent a single TGF at different stages of cellular processing.
The two peaks of ovine fetal TGF-like activity detected in fractions eluting from Bio-Gel coincided with two peaks of EGF receptor-binding activity. Two lines of evidence suggest that the reduction in the binding of 1251-mouse EGF to EGF receptors caused by active Bio-Gel fractions did not result from degradation of the EGF tracer or protelysis of the EGF receptor: 1) the specific binding of radiolabeled EGF which had previously been incubated with active Bio-Gel fractions was comparable to the specific binding of EGF tracer incubated with assay buffer alone; ahd 2) the specific binding of IZSI-EGF to hepatic microsomes preincubated with active Bio-Gel fractions was comparable to the specific binding of I2'I-EGF to hepatic microsomes preincubated in receptor assay buffer alone. Thus, the abili-ty of Bio-Gel column fractions to compete with 1251-EGF for binding to sheep hepatic receptors resulted from the binding of ovine fetal EGFlike TGF(s) to EGF receptors. The failure of receptor-active fractions to compete with "'I-mouse EGF for binding to specific antimouse EGF antibody is consistent with previous studies demonstrating that TGFs do not cross-react with mouse EGF in a RIA (18, 19, 35) .
The members of thk TGF5family have been classified as type a or type P TGFs on the basis of the differential binding of the peptides to EGF receptors and the differential effects of the peptides on colony foimation'of NRK fibroblasts in soft agar (35) . TGF-CY competes with EGF for binding to EGF receptors and stimulates the formation of small colonies (850-3 100 pM2) of NRK fibroblasts in soft agar. TGF-P, on the other hand, does not bind to EGF receptors but induces the formation of large colonies (>3 100 pM2) of NRK cells in soft agar if cultured in the presence of TGF-a or EGF: TGF-(3 alone has no transforming activity for NRK cells in the soft agar assay. The demonstration that acid-ethanol extracts of ?vine fetal kidney bind to EGF receptors and stimulate the foi'mation of large colonies of NRK cells in soft agar suggests.;he presence of TGF-a as well as TGF-0-like activity in the ovine fetus. When acid-ethanol eqtracts of ovine fetal kidney were chromatographed on Bio-Gel, neither TGF-like colony-forming activity nor EGF receptor-binding activity were detected in fractions coeluting with 1251-movse, EGF. This observation suggests that ovine TGF may predominate in the ovine fetus and may play an EGF-like role in avino fetal development. This hypothesis is consistent with previous studies demonstrating that the concentration of TGF a in whole extracts of mouse embryos greatly exceeds that of mouse EGF (34) . We cannot, however, exclude the possibility that ovine .EGF elutes from Bio-Gel in a manner which differs from that of mouse EGF. Moreover, the relative concentrations of TGF and EGF in ovine fetal tissues may vary at different stages of development.
Specific, high affinity EGF binding sites were detected in the livers of fetal, postnatal nonpregnant, and pregnant sheep. EGF binding sites in fetal liver were demonstrable as early as midgestation. Because both EGF and TGF-CY bind with high affinity to EGF receptors (18, 19, 35) , these EGF binding sites in ovine fetal liver may represent receptors for EGF and/or TGF-a. The number of fetal EGF receptors per mg protein increased during the latter part of gestation, exceeding the number of EGF binding sites in the liver of the pregnant ewe and reaching a peak at the time of birth. Studies by Adamson and Meek (3) in the fetal mouse demonstrated a similar marked increase in the number of hepatic EGF receptors during the latter third of gestation. The cause for the late-gestational increase in fetal EGF binding sites is unclear. Studies in postnatal rats indicate that the number of hepatic EGF receptors is dependent on thyroid status (36) . Since the plasma concentrations of total and free thyroxine in the ovine fetus increase dramatically from day 60 until term and exceed the concentrations of total and free thyroxine in the pregnant ewe (37) , the number of EGF receptors in ovine fetal liver may be regulated in part by thyroid hormone.
Our studies provide evidence for the existence of EGF-like TGF activity in the sheep fetus. The presence of EGF-like TGF activity in ovine fetal kidney and high affinity EGF receptors in ovine fetal liver strongly implicate a role for TGF in the growth and development of the ovine fetus.
